The principles of antibody therapy for infectious diseases with relevance for COVID-19

A Casadevall, L Pirofski, MJ Joyner - MBio, 2021 - Am Soc Microbiol
Antibody therapies such as convalescent plasma and monoclonal antibodies have emerged
as major potential therapeutics for coronavirus disease 2019 (COVID-19). Immunoglobulins …

Passive immunotherapy against SARS-CoV-2: from plasma-based therapy to single potent antibodies in the race to stay ahead of the variants

WR Strohl, Z Ku, Z An, SF Carroll, BA Keyt, LM Strohl - BioDrugs, 2022 - Springer
The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people
infected and nearly six million dead worldwide, making it the most significant pandemic …

RBD-specific polyclonal F (ab) 2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind …

G Lopardo, WH Belloso, E Nannini, M Colonna… - …, 2021 - thelancet.com
Background passive immunotherapy is a therapeutic alternative for patients with COVID-19.
Equine polyclonal antibodies (EpAbs) could represent a source of scalable neutralizing …

Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?

J Zhang, H Zhang, L Sun - MAbs, 2022 - Taylor & Francis
Early humoral immune responses to severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) are dominated by IgM and IgA antibodies, which greatly contribute to virus …

Extracellular vesicles in COVID-19 prognosis, treatment, and vaccination: An update

A Hernández-Díazcouder, C Díaz-Godínez… - Applied Microbiology …, 2023 - Springer
The lethality of the COVID 19 pandemic became the trigger for one of the most meteoric
races on record in the search for strategies of disease control. Those include development of …

Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody

G Valenzuela Nieto, R Jara, D Watterson… - Scientific reports, 2021 - nature.com
Despite unprecedented global efforts to rapidly develop SARS-CoV-2 treatments, in order to
reduce the burden placed on health systems, the situation remains critical. Effective …

Polyclonal F (ab') 2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency

LER Cunha, AA Stolet, MA Strauch, VAR Pereira… - Iscience, 2021 - cell.com
We used the recombinant trimeric spike (S) glycoprotein in the prefusion conformation to
immunize horses for the production of hyperimmune globulins against SARS-CoV-2. Serum …

The road towards polyclonal anti-SARS-CoV-2 immunoglobulins (hyperimmune serum) for passive immunization in COVID-19

D Focosi, M Tuccori, M Franchini - Life, 2021 - mdpi.com
Effective treatments specific for COVID-19 are still lacking. In the setting of passive
immunotherapies based on neutralizing antibodies (nAbs), randomized controlled trials of …

Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19

G Leon, M Herrera, M Vargas, M Arguedas… - Scientific reports, 2021 - nature.com
In the current global emergency due to SARS-CoV-2 outbreak, passive immunotherapy
emerges as a promising treatment for COVID-19. Among animal-derived products, equine …

Facing up to the COVID-19 pandemic in Argentina

GA Rabinovich, J Geffner - Nature Immunology, 2021 - nature.com
From the onset of the SARS-CoV-2 pandemic and following the creation of the 'Coronavirus
Unit', Argentinean scientists and technologists have contributed by leading basic and …